128 related articles for article (PubMed ID: 10474257)
1. Cytotoxicity and in-vivo tolerance of FdUMP[10]: a novel pro-drug of the TS inhibitory nucleotide FdUMP.
Gmeiner WH; Skradis A; Pon RT; Liu J
Nucleosides Nucleotides; 1999; 18(6-7):1729-30. PubMed ID: 10474257
[TBL] [Abstract][Full Text] [Related]
2. Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
Liu J; Kolath J; Anderson J; Kolar C; Lawson TA; Talmadge J; Gmeiner WH
Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):481-6. PubMed ID: 10555156
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
Liu C; Willingham M; Liu J; Gmeiner WH
Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
[TBL] [Abstract][Full Text] [Related]
4. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
6. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
7. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
Liu J; Kolar C; Lawson TA; Gmeiner WH
J Org Chem; 2001 Aug; 66(17):5655-63. PubMed ID: 11511236
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
Farquhar D; Khan S; Srivastva DN; Saunders PP
J Med Chem; 1994 Nov; 37(23):3902-9. PubMed ID: 7966151
[TBL] [Abstract][Full Text] [Related]
9. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
Pardee TS; Gomes E; Jennings-Gee J; Caudell D; Gmeiner WH
Blood; 2012 Apr; 119(15):3561-70. PubMed ID: 22362039
[TBL] [Abstract][Full Text] [Related]
10. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition.
Sinnige HA; Timmer-Bosscha H; Peters GF; De Vries EG; Mulder NH
Anticancer Res; 1993; 13(5A):1335-40. PubMed ID: 8239504
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
Tobias SC; Borch RF
J Med Chem; 2001 Dec; 44(25):4475-80. PubMed ID: 11728193
[TBL] [Abstract][Full Text] [Related]
12. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity.
Jennings-Gee J; Pardee TS; Gmeiner WH
Exp Hematol; 2013 Feb; 41(2):180-188.e4. PubMed ID: 23085462
[TBL] [Abstract][Full Text] [Related]
13. Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
Berne MH; Gustavsson BG; Almersjö O; Spears PC; Frösing R
Cancer Chemother Pharmacol; 1986; 16(3):237-42. PubMed ID: 3698165
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate.
Peters GJ; van Groeningen CJ; Laurensse EJ; Pinedo HM
Eur J Cancer; 1991; 27(3):263-7. PubMed ID: 1827310
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
16. Novel chemical strategies for thymidylate synthase inhibition.
Gmeiner WH
Curr Med Chem; 2005; 12(2):191-202. PubMed ID: 15638735
[TBL] [Abstract][Full Text] [Related]
17. Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP).
Sun YW; Chen KM; Kwon CH
Mol Pharm; 2006; 3(2):161-73. PubMed ID: 16579645
[TBL] [Abstract][Full Text] [Related]
18. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
19. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Johnston PG; Drake JC; Trepel J; Allegra CJ
Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
